ARWR Arrowhead Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ARWR
Price (delayed)
$40.31
Market cap
$5.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.24
Enterprise value
$6.16B
Relative Growth:
37
Relative Strength:
96
Relative Valuation:
9
Relative Profitability:
49
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger
Highlights
ARWR's EPS has soared by 73% YoY and by 9% from the previous quarter
The gross profit is up by 5% QoQ
The net income has surged by 72% year-on-year but it has declined by 3.1% since the previous quarter
The equity has soared by 58% YoY but it has contracted by 24% from the previous quarter
Key stats
What are the main financial stats of ARWR
Market
Valuations
Earnings
Shares outstanding
138.26M
Market cap
$5.57B
Enterprise value
$6.16B
Price to earnings (P/E)
N/A
Price to book (P/B)
10.66
Price to sales (P/S)
9.78
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.75
Revenue
$572.98M
Gross profit
$572.98M
Operating income
-$107.96M
Net income
-$148.42M
EBIT
-$64.14M
EBITDA
-$41.57M
Free cash flow
-$17.62M
Per share
Balance sheet
Liquidity
EPS
-$1.24
EPS diluted
-$1.27
Free cash flow per share
-$0.13
Book value per share
$3.78
Revenue per share
$4.12
TBVPS
$9.88
Total assets
$1.38B
Total liabilities
$860.81M
Debt
$713.29M
Equity
$522.31M
Working capital
$752.39M
Debt to equity
1.37
Current ratio
4.87
Quick ratio
4.68
Net debt/EBITDA
-14.04
Margins
Efficiency
Dividend
EBITDA margin
-7.3%
Gross margin
100%
Net margin
-25.9%
Operating margin
-18.8%
Return on assets
-11.6%
Return on equity
-41.1%
Return on invested capital
-3.6%
Return on capital employed
-5.4%
Return on sales
-11.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARWR stock price
How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
6.5%
1 week
0.05%
1 month
11.6%
1 year
95.96%
YTD
114.41%
QTD
16.87%
Financial performance
How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$572.98M
Gross profit
$572.98M
Operating income
-$107.96M
Net income
-$148.42M
Gross margin
100%
Net margin
-25.9%
Arrowhead Pharmaceuticals's net margin has surged by 99% YoY
The operating margin has surged by 99% year-on-year and by 13% since the previous quarter
The operating income has surged by 80% year-on-year and by 9% since the previous quarter
The net income has surged by 72% year-on-year but it has declined by 3.1% since the previous quarter
Price vs fundamentals
How does ARWR's price correlate with its fundamentals
Growth
What is Arrowhead Pharmaceuticals's growth rate over time
Valuation
What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
10.66
P/S
9.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.75
ARWR's EPS has soared by 73% YoY and by 9% from the previous quarter
The equity has soared by 58% YoY but it has contracted by 24% from the previous quarter
The price to book (P/B) is 33% lower than the last 4 quarters average of 16.0 and 20% lower than the 5-year quarterly average of 13.4
The price to sales (P/S) is 98% less than the last 4 quarters average of 399.8 and 92% less than the 5-year quarterly average of 122.7
The company's revenue rose by 5% QoQ
Efficiency
How efficient is Arrowhead Pharmaceuticals business performance
ARWR's ROS has soared by 100% YoY and by 22% from the previous quarter
Arrowhead Pharmaceuticals's return on invested capital has surged by 93% YoY and by 25% QoQ
The company's return on assets has surged by 83% YoY and by 7% QoQ
The company's return on equity has surged by 76% YoY and by 11% QoQ
Dividends
What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARWR.
Financial health
How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 60% higher than its total liabilities
The total liabilities has surged by 58% year-on-year but it has declined by 3.2% since the previous quarter
ARWR's total assets has soared by 56% YoY but it is down by 12% QoQ
Arrowhead Pharmaceuticals's debt is 37% higher than its equity
The equity has soared by 58% YoY but it has contracted by 24% from the previous quarter
Arrowhead Pharmaceuticals's debt has surged by 57% YoY but it has decreased by 3.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.